21
Sep
Adolescents living with HIV in low- and middle-income African countries experienced better viral suppression and a lower rate of rebound when treated with eight-weekly long-acting injections rather than standard daily pills, a major new clinical trial published in The Lancet has revealed. Conducted across five clinics in Kenya, South Africa, Uganda, and Zimbabwe, the LATA trial evaluated 476 participants aged 12 to 19 who had been stable on oral therapy for over a year, finding that only two adolescents (1 per cent) in the injectable arm suffered viral rebound at 96 weeks compared to 15 adolescents (6 per cent) in…
